News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Apitope Grows Operations with Move to St Brandon's House, Bristol, UK

10/1/2010 12:14:21 PM

Bristol, England / Hasselt, Belgium – 01 October 2010: Apitope International N.V., the biopharmaceutical company developing peptide therapies for autoimmune diseases, announced today that it has relocated its UK subsidiary HQ to larger premises at St Brandon’s House in Bristol, England as a result of significant growth in Apitope’s business and staff. St Brandon’s House is a distinguished Grade II listed Georgian building ideally located in the heart of Bristol's business district but remaining close to the university.

Apitope was spun out of Bristol University in 2002, and since then has raised significant investment from specialist life sciences investors. In January 2009, Apitope signed an agreement with Merck Serono for the development and commercialisation of its lead product ATX-MS-1467. ATX-MS-1467 is a potentially disease-modifying therapy for the treatment of MS.

Keith Martin, CEO of Apitope said:

“Apitope has enjoyed a number of successful years in the Set Squared Centre at University Gate East and the larger premises at St Brandon’s House allow us to embark on the next phase of growth as we expand our management team, staff and business activities.”

For further information:

Apitope International N.V. Dr. Keith Martin, CEO +44 (0)117 920 0062

Capital MS&L Limited Mary Clark, Head of Life Sciences +44 20 7307 5330

About Apitope

Apitope is a European biotechnology company focusing on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease. It has headquarters in Hasselt, Belgium and a subsidiary in Bristol, UK.

The Company is developing potential therapies to selectively treat the underlying cause of a range of autoimmunediseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system.

Its patented, leading edge, high speed discovery platform enables it to identify and design innovative peptide-based therapies and diagnostics and it has an impressive pipeline of products in development.

Apitope has a highly experienced management team, with a proven track record in discovering and developing innovative therapeutics. Its lead product for treating multiple sclerosis is in Phase I development and is partnered with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

For more information, please go to

Read at

comments powered by Disqus